News
-
-
-
PRESS RELEASE
Dermapharm Holding SE posts strong results for Q3 2024, Arkopharma (France) back above prior-year EBITDA levels for first time
Dermapharm Holding SE reports strong Q3 2024 results with consolidated revenue up 2.7% to EUR 890.1 million. Adjusted EBITDA margin improves. Outlook confirms forecasted targets for 2024 -
-
-
PRESS RELEASE
Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies
Dermapharm Holding SE reports 7.3% rise in unadjusted EBITDA to EUR 147.0 million, driven by organic growth in branded pharmaceuticals segment. High-revenue expected in H2. Full report at https://ir.dermapharm.de/en -
-
-
-
